Okyo Pharma Ltd. (OKYO)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN Summary
OKYO Pharma reports favorable outcomes from Phase 2 neuropathic corneal pain study
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing treatments for neuropathic corneal pain (NCP), said patients treated with its investigational therapy urcosimod in its recently completed Phase 2 trial showed improvements in corneal nerve structure, a potential indicator of nerve restoration. The 18-patient, randomized, double-masked, placebo-controlled trial evaluated corneal nerve health using in vivo confocal microscopy.
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company's Phase 2 trial evaluating urcosimod in patients with neuropathic corneal pain. Jacob explained that neuropathic corneal pain is a severe nerve pain condition without any FDA-approved treatments, describing it as “like having a spinal cord injury in your eye.
OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy
OKYO Pharma Ltd (NASDAQ:OKYO) announced it has secured $1.9 million in non-dilutive funding to support the development of urcosimod, its lead drug candidate for neuropathic corneal pain (NCP). NCP is a chronic, nerve-related ocular condition that currently has no US Food and Drug (FDA)-approved treatments.
Okyo Pharma Ltd. (OKYO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Okyo Pharma Ltd. ever had a stock split?
Okyo Pharma Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Gary S. Jacob CEO | NASDAQ (CM) Exchange | 679345108 CUSIP |
| GB Country | 3 Employees | - Last Dividend | - Last Split | 17 May 2022 IPO Date |
Overview
OKYO Pharma Limited is a clinical-stage biopharmaceutical company based in the United Kingdom, dedicated to the development of innovative therapeutics for patients afflicted with inflammatory eye diseases and ocular pain. The company, founded in 2007 and headquartered in London, has taken significant strides in the biopharmaceutical field, particularly focusing on conditions that affect eye health. With a strong commitment to addressing unmet medical needs, OKYO Pharma is at the forefront of researching and developing advanced treatments that promise to alleviate suffering and improve the quality of life for patients facing eye-related afflictions.
Products and Services
- OK-101
This lead preclinical product candidate is currently in Phase II clinical trials and represents OKYO Pharma’s pioneering approach to treating dry eye disease. Dry eye disease is a prevalent condition that can significantly impact an individual's quality of life, causing discomfort, and in severe cases, impairing vision. OK-101 is being developed with the aim of providing a novel, effective treatment option for patients who suffer from this condition, potentially improving their symptoms and overall eye health.
- OK-201
Another innovative venture by OKYO Pharma, OK-201 is a preclinical analogue candidate derived from bovine adrenal medulla. This lipidated-peptide is being developed for the treatment of neuropathic chronic pain, a condition that remains challenging to manage with current treatment options. By focusing on novel pathways and mechanisms, OKYO Pharma aims to contribute an important solution to the field of pain management, particularly for patients whose quality of life is severely affected by chronic pain conditions.
Contact Information
